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XUE ET AL.: Prognostic Value of High-Sensitivity C-reactive Protein in Patients with Chronic Heart Failure.
Objectives: To determine whether High-Sensitivity C-reactive Protein (hsCRP) has Prognostic value in patients
with chronic heart failure. Methods: Serum hsCRP levels were measured with high-sensitivity assay (IMMAGE
Immunochemistry Systems) in 128 patients with CHF and 25 healthy control subjects. Cardiac troponin T (TNT) was
measured by Electrochemiluminescence immunoassay on Elecsys1010 automatic analyzer. Cardiac events were
defined as cardiac death and rehospitalization because of worsening heart failure during a mean follow up period of
378±26 days. Results: Circulating levels of hsCRP and TNT were significantly higher (3.85±4.25 mg/L, 0.21±0.15
mg/L, respectively) in patients with CHF than in 25 healthy people (p<0.01, p<0.01, respectively) and increased
with severity of CHF. During a mean follow up period of 378±26 days, forty-two (32.8%) of the 128 patients had
cardiac events. Levels of hsCRP and TNT were significantly higher (p<0.001, p<0.001, respectively) and left
ventricular ejection fraction (LVEF) was significantly lower (p<0.01) in patients with cardiac events than in patients
without cardiac events. When multivariate Cox proportional hazards analysis was performed, we could find that
hsCRP, TNT, and LVEF were independent significant predictors of cardiac events in patients with CHF. (hsCRP:
hazard ratio[HR], 3.81; 95%CI, 2.14-9.35; P=0.024; TNT: HR, 2.61; 95%CI, 1.96-4.31; P=0.012; LVEF: HR,
3.52; 95%CI, 2.36-10.37; P=0.024). A positive correlation was observed between hsCRP and TNT (r=0.493,
p<0.01). A negative correlation was observed between hsCRP and LVEF (r=-0.354, p<0.01). Conclusion: Serum
hsCRP concentrations were elevated in patients with CHF and increased with severity of CHF. It was an independent
significant predictor of cardiac events in patients with CHF. (J HK Coll Cardiol 2004;12:64-69)
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Introduction

Table 1. The characteristics of patients with CHF

The serum concentration of C-reactive protein
(CRP) is mildly elevated in patients with chronic
congestive heart failure (CHF). Standard assay for CRP
lack the sensitivity within the low reference range and
thus cannot be used effectively for routine clinical risk
prediction. Our study was aimed at investigating highsensitivity assay of CRP (hsCRP), a marker of systemic
inflammation, in the context of heart failure, and to
determine if it has prognostic value in patients with
CHF.

Methods
Patients
A total of 128 patients (Chinese) with chronic
heart failure were enrolled in this study. The
diagnosis of chronic heart failure (CHF) was based
on the criteria below produced by the European
Society of Cardiology:1
1. Symptoms of heart failure (at rest or during exercise)
2. Objective evidence of cardiac dysfunction (at rest)
3. Response to treatment directed toward heart failure
(in cases where the diagnosis is in doubt)
The characteristics of patients with CHF were
summarized in Table 1.
All patients had a left ventricular ejection fraction
(LVEF) <40% or had a mean left ventricular endsystolic dimension >55 mm by transthoracic
echocardiography. Ischemic CHF was diagnosed by
coronary angiography (>50% luminal diameter
narrowing in at least 1 major epicardial coronary artery)
or by the history of documented myocardial infarction.
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No. of patients
Age (y)
Sex M/F
No. of diabetics
No. of smokers
Cause of CHF
Ischemic CHF
Non-Ischemic CHF
NYHA n (%)
Class II
Class III
Class IV
Left ventricular ejection fraction
All patients with CHF
Ischemic CHF
Non-Ischemic CHF
Class II
Class III
Class IV

128
62±15
79/49
19
35
75
53
57 (44.5%)
40 (31.3%)
31 (24.2%)
0.37±0.11
0.36±0.09
0.33±0.08
0.36±0.12
0.27±0.12
0.19±0.13

Non-Ischemic CHF was caused by primary dilated
cardiomyopathy (26 patients), valvular heart disease (15
patients), systemic hypertension (12 patients). We
excluded patients with clinical or laboratory evidence
of systemic infection, myocardial infarction within 8
months, pericarditis, cor pulmonale, inflammatory
illness such as arthritis or connective tissue diseases,
any malignancy tumor.
Control population consisted of 25 healthy
Chinese people (men 15, women 10, mean age 59±16
years old). Blood samples from patients were obtained
on the first day of admission. Control blood samples
from 25 healthy people were obtained at fasting
condition. Blood samples were allowed to clot for 30
minutes at room temperature and were centrifuged for
5 minutes. All blood samples were measured without

July/October 2004

J HK Coll Cardiol, Vol 12

XUE ET AL.

frozen within 3 hours after blood samples were obtained.
All patients were followed up by telephone, or through
regular outpatients visits, or when they were
rehospitalized. Mean follow up period was 378±26 days.
Cardiac events was defined as cardiac death and
rehospitalization because of worsening heart failure.

Measurements of hsCRP and TNT
hsCRP was measured by immunoassay with an
autoanalyzer (IMMAGE Immunochemistry Systems,
Beckman Coulter, California). The intra-assay and
inter-assay coefficients of variation for hsCRP were 5%
and 10%, respectively. TNT was measured by
Electrochemiluminescence immunoassay with
Elecsys1010 automatic analyzer (Roche Company).
Inter-assay and intra-assay coefficient of variation were
<4% and <7% respectively. The level of sensitivity is
<1 pmol. LVEF was obtained by 2-dimensional
echocardiography with HDI 3000 echocardiograph
(ALT Company America).

Statistical Analysis
Data were expressed as mean±SD. Patients were
divided into 3 groups according to their NYHA
functional classification. Analysis of variance test was
used to compare the difference of the levels of hsCRP
and TNT among these 3 groups and the 25 control
subjects. The correlation between the levels of hsCRP
and TNT, hsCRP and LVEF were assessed by using
Linear regression analysis. Cox proportional hazards
analysis was performed to determine the significance
of age, sex, LVEF, presence of ischemic heart disease,
the use of statin drugs, and circulating levels of hsCRP
as independent predictors of CHF. Patients were divided
in 2 groups, patients who had major adverse cardiac
events and those who were event-free. T-test for
measurement data and chi-square test for enumeration

data were performed to compare clinical and
hemodynamic characteristics in these 2 groups.

Results
Circulating levels of hsCRP and TNT were
significantly higher (3.85±4.25 mg/L, 0.21±0.15 mg/L,
respectively) in patients with CHF than in 25 healthy
people (p<0.01, p<0.01, respectively) and increased
with severity of CHF. These data were shown in
Table 2. Patients with CHF were divided in 2 groups
according to the causes of their CHF (ischemic vs nonischemic), serum levels of hsCRP had no significant
difference between the 2 groups (4.13±5.12mg/L vs
4.09±5.24 mg/L, p>0.05).
During a mean follow up period of 378±26 days,
forty-two (32.8%) of the 128 patients had cardiac events.
Patients with CHF were divided into 2 groups, patients
with cardiac events and those who were event free.
There were no significant differences in age, sex, causes
of CHF, or medications between the 2 groups. However
levels of hsCRP and TNT were significantly higher
(p<0.001, p<0.001, respectively) and LVEF was
significantly lower (p<0.01) in patients with cardiac
events than in patients without cardiac events. This data
was shown in Table 3.
When multivariate Cox proportional hazards
analysis was performed, we could find that hsCRP,
TNT, and LVEF were independent significant predictors
of cardiac events in patients with CHF. (hsCRP: hazard
ratio [HR], 3.81; 95%CI, 2.14-9.35; P=0.024; TNT: HR,
2.61; 95%CI, 1.96-4.31; P=0.012; LVEF: HR, 3.52;
95%Cl, 2.36-10.37; P=0.024). A positive correlation
was observed between hsCRP and TNT (r=0.493,
p<0.01). A negative correlation was observed between
hsCRP and LVEF (r=-0.354, p<0.01).

Table 2. The concentrations of hsCRP, TNT in patients with CHF and contral subjects
hsCRP (mg/L)
TNT (mg/L)

Control
1.01±0.54
0.003±0.001
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Class II
2.64±3.12
0.143±0.15

Class III
4.51±5.21
0.215±0.17
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Class IV
6.34±7.36
0.45±0.19

P
<0.01
<0.05
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Table 3. Characteristics of patients who had cardiac events and those who were event free
Age (y)
Male (%)
Causes of CHF
Ischemic
Non-ischemic
Medications
Diuretic
Digitalis
β-blockers
ACEI/ARB
Statins
LVEF
hsCRP (mg/L)
TNT (mg/L)

Cardiac events (n=42)
59±8
26 (62%)

Event free (n=86)
62±9
53 (62%)

P
NS
NS

24
18

51
35

NS
NS

39
34
22
32
10
0.22±0.14
6.59±7.69
0.48±0.11

84
70
43
68
21
0.36±0.15
2.46±3.25
0.11±0.02

NS
NS
NS
NS
NS
P<0.01
P<0.001
P<0.001

NS: non significance

Discussion
CHF is the final common pathway of a variety
of cardiac disorder, including ischemic heart disease,
idiopathic dilated cardiomyopathy, and valvular
disease, and is usually progressive. Recent studies
suggest that heart failure may, in part, be an
inflammatory disease.2-4 CRP, an acute phase reactive
protein that increases during the host response to
tissue injury, including that caused by infection,
trauma, malignant disease and chronic inflammatory
conditions,5 is synthesized in the liver, and its serum
concentration is a reliable index of overall
inflammation activity. Several large-scale
prospective epidemiological studies have shown that
plasma levels of hsCRP are a strong independent
predictor of risk of future myocardial infarction,
stroke, peripheral arterial disease, and vascular death
among individuals without known cardiovascular
disease. 6-10 Several studies have shown increased
concentration of CRP in patients with heart failure,11-15
but clinical data about the prognostic value of CRP in
patients with chronic heart failure have been sparse and
inconsistent.11,12,16 Because standard assays for CRP
lack the sensitivity needed to determine levels of
inflammation within low reference range, and thus
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clinical utility of standard CRP is extremely limited to
its prognostic values in patients with CHF. More
recently, with the recognition that inflammation is one
of the mechanisms of CHF and with the availability of
highly sensitive assay systems, we thought that
circulating concentrations of hsCRP may have
prognostic value in patients with CHF.
Our study demonstrated that serum hsCRP
concentration were elevated in patients with CHF and
increased with severity of CHF. Furthermore, this
study had shown that elevated serum hsCRP
concentrations have independent significant
predictive value. In our study we also found that
hsCRP had a positive correlation with TNT and had
a negative correlation with LVEF. The clinical and
basic studies had shown that CRP has a fundamental
role in atherogenesis. 17 Coronary artery disease was
present in 68% of patients with CHF,18 which cause,
in part, elevated serum hsCRP in patients with CHF.
This study also shown that increased hsCRP levels
in patients with CHF was unrelated to the causes of
heart failure, which suggests that CHF is the final
common pathway of a variety of cardiac disorders,
including ischemic heart disease, idiopathic dilated
cardiomyopathy, and valvular heart disease.
Previous studies observed elevated serum levels
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of TNT in patients with CHF, 19-21 and their presence
was associated with adverse outcome.17 Our results are
consistent with the emerging concept that cardiac
troponin elevations reflect ongoing myocardial cell
injury associated with the progression of CHF. Also,
the present study showed a positive correlation between
TNT and hsCRP, speculating that markers specific for
myocardial cell injury or inflammatory effect may detect
different features of the pathophysiologic process of
heart failure.
The mechanisms underlying the pathogenesis and
progression of CHF remain unclear. Different
mechanisms may be involved, such as activations of
sympathetic nerve and renin-angiotensin-aldosterone
systems. Both experimental and clinical studies have
also shown a role for inflammation in the pathogenesis
of heart failure. There is evidence that chronic activation
of the immune system exists during heart failure. Some
patients present evidence of monocyte-macrophage and
lymphocyte activation.22-25 It appears clear that patients
with either ischemic or non-ischemic heart failure show
activation of proinflammatory cytokines (IL-1, IL-6,
tumor necrosis factor-α). Interleukin-6 is a major
inducer of CRP.26 Cardiac decompensation itself and
injuries to other organs such as the liver, kidney, brain,
or skeletal muscle induced by low cardiac output,
hypoperfusion, hypoxia, and venous congestion may
each be sources of interleukin-6, which may in turn
result in the production of CRP in patients with CHF.27
CRP has many pathophysiologic roles in the
inflammatory process.28 It can amplify the inflammatory
response through complement activation, which may
cause myocardial cell apoptosis, and thus ventricular
damage or dysfunction.29 This may resulted in mildly
elevated levels of serum TNT in patients with CHF. In
our study we found that hsCRP had a negative
correlation with LVEF, this indicated a correlation
between hsCRP and myocardial cell damage.
Whether CRP is simply a marker of chronic
systemic inflammation or directly involved in the
pathogenesis of CHF? Whether it can be used as a target
for treatment of CHF? Further studies will be needed
to answer this question.
In conclusion, serum hsCRP concentrations were
elevated in patients with CHF and increased with
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severity of CHF. It was an independent significant
predictor of cardiac events in patients with CHF.
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